Selected research
Industry Research
Nortriptyline Industry Research Report 2026
Market perspective
The global Nortriptyline market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Nortriptyline is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Nortriptyline is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Nortriptyline is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Nortriptyline include Teva Pharmaceuticals, Novartis, Mylan Pharmaceuticals, Eli Lilly and Company, Zatuk, Watson Laboratories, Taro Pharmaceuticals, Ranbaxy Pharmaceuticals and Mayne Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Nortriptyline market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nortriptyline Market by Company
Teva Pharmaceuticals
Novartis
Mylan Pharmaceuticals
Eli Lilly and Company
Zatuk
Watson Laboratories
Taro Pharmaceuticals
Ranbaxy Pharmaceuticals
Mayne Pharma
EU-Pharma
Dainippon Sumitomo Pharma
Nortriptyline Segment by Type
Capsule
Solution
Nortriptyline Segment by Application
Hospital
Drug Store
Nortriptyline Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nortriptyline market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nortriptyline and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nortriptyline.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nortriptyline manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nortriptyline by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nortriptyline in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Solution
Applications
- Hospital
- Drug Store
Companies covered
- Teva Pharmaceuticals
- Novartis
- Mylan Pharmaceuticals
- Eli Lilly and Company
- Zatuk
- Watson Laboratories
- Taro Pharmaceuticals
- Ranbaxy Pharmaceuticals
- Mayne Pharma
- EU-Pharma
- Dainippon Sumitomo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nortriptyline Market Size (2021-2032)
- 2.2.2 Global Nortriptyline Sales (2021-2032)
- 2.2.3 Global Nortriptyline Market Average Price (2021-2032)
- 2.3 Nortriptyline by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capsule
- 2.3.3 Solution
- 2.4 Nortriptyline by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug Store
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nortriptyline Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Nortriptyline Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Nortriptyline Revenue of Manufacturers (2021-2026)
- 3.4 Global Nortriptyline Average Price by Manufacturers (2021-2026)
- 3.5 Global Nortriptyline Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Nortriptyline, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nortriptyline, Product Type & Application
- 3.8 Global Manufacturers of Nortriptyline, Established Date
- 3.9 Global Nortriptyline Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals
- 4.1.1 Teva Pharmaceuticals Company Information
- 4.1.2 Teva Pharmaceuticals Business Overview
- 4.1.3 Teva Pharmaceuticals Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceuticals Nortriptyline Product Portfolio
- 4.1.5 Teva Pharmaceuticals Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Nortriptyline Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Mylan Pharmaceuticals
- 4.3.1 Mylan Pharmaceuticals Company Information
- 4.3.2 Mylan Pharmaceuticals Business Overview
- 4.3.3 Mylan Pharmaceuticals Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Pharmaceuticals Nortriptyline Product Portfolio
- 4.3.5 Mylan Pharmaceuticals Recent Developments
- 4.4 Eli Lilly and Company
- 4.4.1 Eli Lilly and Company Company Information
- 4.4.2 Eli Lilly and Company Business Overview
- 4.4.3 Eli Lilly and Company Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly and Company Nortriptyline Product Portfolio
- 4.4.5 Eli Lilly and Company Recent Developments
- 4.5 Zatuk
- 4.5.1 Zatuk Company Information
- 4.5.2 Zatuk Business Overview
- 4.5.3 Zatuk Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zatuk Nortriptyline Product Portfolio
- 4.5.5 Zatuk Recent Developments
- 4.6 Watson Laboratories
- 4.6.1 Watson Laboratories Company Information
- 4.6.2 Watson Laboratories Business Overview
- 4.6.3 Watson Laboratories Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Watson Laboratories Nortriptyline Product Portfolio
- 4.6.5 Watson Laboratories Recent Developments
- 4.7 Taro Pharmaceuticals
- 4.7.1 Taro Pharmaceuticals Company Information
- 4.7.2 Taro Pharmaceuticals Business Overview
- 4.7.3 Taro Pharmaceuticals Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Taro Pharmaceuticals Nortriptyline Product Portfolio
- 4.7.5 Taro Pharmaceuticals Recent Developments
- 4.8 Ranbaxy Pharmaceuticals
- 4.8.1 Ranbaxy Pharmaceuticals Company Information
- 4.8.2 Ranbaxy Pharmaceuticals Business Overview
- 4.8.3 Ranbaxy Pharmaceuticals Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Ranbaxy Pharmaceuticals Nortriptyline Product Portfolio
- 4.8.5 Ranbaxy Pharmaceuticals Recent Developments
- 4.9 Mayne Pharma
- 4.9.1 Mayne Pharma Company Information
- 4.9.2 Mayne Pharma Business Overview
- 4.9.3 Mayne Pharma Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mayne Pharma Nortriptyline Product Portfolio
- 4.9.5 Mayne Pharma Recent Developments
- 4.10 EU-Pharma
- 4.10.1 EU-Pharma Company Information
- 4.10.2 EU-Pharma Business Overview
- 4.10.3 EU-Pharma Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 EU-Pharma Nortriptyline Product Portfolio
- 4.10.5 EU-Pharma Recent Developments
- 4.11 Dainippon Sumitomo Pharma
- 4.11.1 Dainippon Sumitomo Pharma Company Information
- 4.11.2 Dainippon Sumitomo Pharma Business Overview
- 4.11.3 Dainippon Sumitomo Pharma Nortriptyline Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Dainippon Sumitomo Pharma Nortriptyline Product Portfolio
- 4.11.5 Dainippon Sumitomo Pharma Recent Developments
5 Global Nortriptyline Market Scenario by Region
- 5.1 Global Nortriptyline Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Nortriptyline Sales by Region: 2021-2032
- 5.2.1 Global Nortriptyline Sales by Region: 2021-2026
- 5.2.2 Global Nortriptyline Sales by Region: 2027-2032
- 5.3 Global Nortriptyline Revenue by Region: 2021-2032
- 5.3.1 Global Nortriptyline Revenue by Region: 2021-2026
- 5.3.2 Global Nortriptyline Revenue by Region: 2027-2032
- 5.4 North America Nortriptyline Market Facts & Figures by Country
- 5.4.1 North America Nortriptyline Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Nortriptyline Sales by Country (2021-2032)
- 5.4.3 North America Nortriptyline Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Nortriptyline Market Facts & Figures by Country
- 5.5.1 Europe Nortriptyline Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Nortriptyline Sales by Country (2021-2032)
- 5.5.3 Europe Nortriptyline Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Nortriptyline Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nortriptyline Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Nortriptyline Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Nortriptyline Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nortriptyline Market Facts & Figures by Country
- 5.7.1 South America Nortriptyline Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Nortriptyline Sales by Country (2021-2032)
- 5.7.3 South America Nortriptyline Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Nortriptyline Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nortriptyline Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Nortriptyline Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Nortriptyline Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Nortriptyline Sales by Type (2021-2032)
- 6.1.1 Global Nortriptyline Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Nortriptyline Sales Market Share by Type (2021-2032)
- 6.2 Global Nortriptyline Revenue by Type (2021-2032)
- 6.2.1 Global Nortriptyline Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Nortriptyline Revenue Market Share by Type (2021-2032)
- 6.3 Global Nortriptyline Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Nortriptyline Sales by Application (2021-2032)
- 7.1.1 Global Nortriptyline Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Nortriptyline Sales Market Share by Application (2021-2032)
- 7.2 Global Nortriptyline Revenue by Application (2021-2032)
- 7.2.1 Global Nortriptyline Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Nortriptyline Revenue Market Share by Application (2021-2032)
- 7.3 Global Nortriptyline Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nortriptyline Value Chain Analysis
- 8.1.1 Nortriptyline Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nortriptyline Production Mode & Process
- 8.2 Nortriptyline Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nortriptyline Distributors
- 8.2.3 Nortriptyline Customers
9 Global Nortriptyline Analyzing Market Dynamics
- 9.1 Nortriptyline Industry Trends
- 9.2 Nortriptyline Industry Drivers
- 9.3 Nortriptyline Industry Opportunities and Challenges
- 9.4 Nortriptyline Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst